Caas Capital Management LP Calliditas Therapeutics Ab Transaction History
Caas Capital Management LP
- $1.31 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding CALT
# of Institutions
24Shares Held
871KCall Options Held
1.5KPut Options Held
32.4K-
Bvf Inc San Francisco, CA750KShares$29.4 Million0.47% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M50.6KShares$1.98 Million0.0% of portfolio
-
Ironwood Investment Management LLC Boston, MA25.5KShares$999,7760.27% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il14.6KShares$571,9380.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA10.3KShares$402,7550.0% of portfolio
About Calliditas Therapeutics AB
- Ticker CALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,624,800
- Market Cap $1.04B
- Description
- Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...